Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 14, 2022 16:43 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
November 10, 2022 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

– BDC-1001 dose-escalation clinical trial on track to complete recruitment by year-end 2022– BDC-3042 on track to enter the clinic in 2023; new preclinical data presented at SITC 2022– Cash balance of...
November 07, 2022 08:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting

REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
November 01, 2022 08:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the...
August 31, 2022 07:30 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the...
August 10, 2022 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

– BDC-1001 monotherapy and combination dose-escalation portion of the trial in HER2-expressing solid tumors on track to complete this year– New portfolio prioritization and capital allocation strategy...
May 27, 2022 08:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022

- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present - REDWOOD CITY, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq:...
May 12, 2022 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

– BDC-1001 monotherapy and OPDIVO® combination trials progressing toward data readouts in second half of 2022 – Cash balance of $246.8 million expected to fund key milestones and operations into...
April 07, 2022 08:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference

REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that...
March 30, 2022 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights

BDC-1001 for the treatment of patients with HER2-expressing solid tumors on track for recommended Phase 2 dose identification later in 2022; BDC-1001 combination study arm with OPDIVO® (nivolumab)...